Xytide Biotech, a leading distributor of cutting-edge medical aesthetics technologies, has announced the TGA approval and launch of e.p.t.q. (pronounced Epitique) a highly anticipated premium hyaluronic acid (HA) dermal filler from Korea.
Boasting a loyal following across more than 58 countries and with over 2 million syringes sold annually1, e.p.t.q has swiftly gained recognition as the ideal filler since 2017, due to its remarkable rheological properties2, high patient satisfaction4, and outstanding safety profile.3,4
“e.p.t.q. is unlike any other product in the market.” stated Troy Guthrie, CEO of Xytide Biotech. “With the current shift towards regenerative aesthetics, there is significant demand for Dermal Fillers that produce outstanding results with less product and that is exactly where e.p.t.q. shines.”
One of e.p.t.q’s key strengths lies in its highly cohesive and viscoelastic2 gel that offers a high lifting capacity with less product and can molded to enhance definition while remaining forgiving to the tissue4.
The range is concise offering three products (S100, S300, S500) with the same highconcentration of HA (24mg/mL) but with different crosslinking ratios for diverse indications.
“Our Korean manufacturer has ingeniously capitalised on the weaknesses of past dermal fillers and combined them with the most desirable characteristics for a truly remarkable product.” Dr Django Nathan, Medical Director at Xytide Biotech “Once you try e.p.t.q. you will feel and see the difference”.
The meticulously controlled 9-step manufacturing process enables e.p.t.q. to maintain a low degree of modification1 (<1.89% MoD) with fine homogenous particles1 for ease of injection and predictable results.
- 2 million syringes sold each year across 58 countries.1
- e.p.t.q. provides strong projection using less product.
- The ideal filler due to its exceptional rheological properties.4
- Easy to inject, natural results and a strong safety profile.3,4
For more information about e.p.t.q. and to place an order, please email info@xytide.com.au or visit www.xytide.com.au
To view the ARTG listing follow the below links:
S100 – https://www.tga.gov.au/resources/artg/441993
S300 – https://www.tga.gov.au/resources/artg/441994
S500 – https://www.tga.gov.au/resources/artg/441992
About Xytide Biotech
Our mission is to empower aesthetic professionals with access to cutting-edge, innovative molecular technologies from around the globe. Why? Because at Xytide we believe that science and technology exist to make our lives happier, easier and longer so it is our passion to elevate the local market with meticulously sourced, high-quality products.
References: 1.Data on file. 2. Lee, W., Hwang, S. G., Oh, W., Kim, C. Y., Lee, J. L., & Yang, E. J. (2020). Practical guidelines for hyaluronic acid soft-tissue filler use in facial rejuvenation. Dermatologic Surgery, 46(1), 41-49. 3. Lee, Won, et al ‘Safe Glabellar Wrinkle Correction with Soft Tissue Filler using Doppler Ultrasound’ Aesthetic Surgery Journal (2020) 4. Lee, Won, et al ‘Clinical application of a new hyaluronic acid filler based on its rheological properties and the anatomical site of injection’ Biomedical Dermatology 2.1 (2018):22
